Overview
With only 10-15% of new venture start ups succeeding, it is important that investments are carefully evaluated and nurtured to become a success. Today, many VCs and angel groups are passive investors that chase industry hype waves in the hope of large returns. This leaves investor groups learning years down the road that their investment will not pay off and it leaves founders little chance of achieving their dreams of changing the world within healthcare.
We are a boutique Healthcare & Life Science investment group with a hands-on approach to identifying quality companies, mentoring founders and de-risking investments. It is said, that you should invest in what you know. Our Big Tree Innovation Fund co-founders each have over 35 years of expertise in the healthcare space and have worked in a variety of roles and companies from start up to large scale businesses and know what it takes to position, market and succeed in healthcare.
We are positioned in Boston with the Mansfield Bio-Incubator and in San Diego with Aquillius to bring a national U.S. ecosystem of healthcare investors and experts.
Boston Ecosystem
San Diego Ecosystem
We only focus in Healthcare & Life Sciences and bring together a national network of industry experts and investors to help innovative companies navigate today’s complex healthcare ecosystem. Our Executive Fellows in Residence are successful founders, senior healthcare, life science, and innovation leaders who bring decades of experience to the Big Tree Start Up Academy and Global Gateway Program. They serve as expert faculty in our bootcamps, masterclasses and U.S. Market gateway to guide founders through the realities of fundraising, FDA pathways and commercialization.
Our funding objective is to raise between $150K to $2MM in seed to series A capital for each funding round. We seek minority or lead investments depending on the size of the round. We partner with VCs, family offices, venture banks, angel groups, corporate ventures to ensure that the round is closed and a company adequately capitalized. We are looking for companies that have a clear path to penetrate markets and will lead to significant step-ups in valuation. Our target is a 5 to 10x return within 3 to 5 years.